Skip to main content
Erschienen in: Die Dermatologie 12/2019

12.11.2019 | Supportivtherapie | CME

Supportivtherapie und Nebenwirkungsmanagement in der Dermatoonkologie

verfasst von: Dr. Laura von Dücker, Svea Hüning, Katharina Kähler, Patrick Terheyden, Dorothée Nashan

Erschienen in: Die Dermatologie | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im Rahmen der Supportivtherapie werden Beschwerden, die durch die Tumorerkrankung selbst oder durch die antitumorale Therapie entstehen, sowie psychosoziale Belange berücksichtigt. Die Medikamente, die nun seit einigen Jahren in der modernen Dermatoonkologie eingesetzt werden, führen zu einem neuartigen Nebenwirkungsspektrum. Unter Einsatz der Immuntherapien kommt es zu einer Reihe entzündlicher, immunvermittelter Nebenwirkungen, die praktisch jedes Organ betreffen können. Auch die zielgerichteten Therapien haben spezifische Nebenwirkungen. Grundsätzlich hängt das Management der Nebenwirkungen von ihrer Schwere ab. Neben Therapiepausen und Dosismodifikationen werden bei immuntherapiebedingten Nebenwirkungen systemische Immunsuppressiva eingesetzt. Unterstützend wird eine symptomatische Therapie angeboten. Durch die zusätzliche Berücksichtigung psychosozialer Probleme kann die Lebensqualität von Krebspatienten gebessert werden.
Literatur
3.
Zurück zum Zitat Radbruch L, Payne S et al (2009) White Paper on standards and norms for hospice and palliative care in Europe: part 1. Eur J Palliat Care 16(6):278–289 Radbruch L, Payne S et al (2009) White Paper on standards and norms for hospice and palliative care in Europe: part 1. Eur J Palliat Care 16(6):278–289
4.
Zurück zum Zitat Smyth JF (2008) Disclosing gaps between supportive and palliative care: the past 20 years. Support Care Cancer 16(2):109–111PubMed Smyth JF (2008) Disclosing gaps between supportive and palliative care: the past 20 years. Support Care Cancer 16(2):109–111PubMed
6.
Zurück zum Zitat Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34PubMedPubMedCentral Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34PubMedPubMedCentral
7.
Zurück zum Zitat Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4‑year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480–1492PubMed Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4‑year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480–1492PubMed
8.
Zurück zum Zitat Terheyden P, Krackhardt A, Eigentler T (2019) Systemtherapie des Melanoms. Einsatz von Immuncheckpoint-Inhibitoren und Hemmung von intrazellulärer Signaltransduktion. Dtsch Arztebl Int 116(29–30):497–504PubMedPubMedCentral Terheyden P, Krackhardt A, Eigentler T (2019) Systemtherapie des Melanoms. Einsatz von Immuncheckpoint-Inhibitoren und Hemmung von intrazellulärer Signaltransduktion. Dtsch Arztebl Int 116(29–30):497–504PubMedPubMedCentral
9.
Zurück zum Zitat Migden MR, Rischin D, Schmults CD et al (2018) PD‑1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379(4):341–351PubMed Migden MR, Rischin D, Schmults CD et al (2018) PD‑1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379(4):341–351PubMed
10.
Zurück zum Zitat Villani A, Fabbrocini G, Costa C et al (2019) Merkel cell carcinoma: therapeutic update and emerging therapies. Dermatol Ther (Heidelb) 9(2):209–222 Villani A, Fabbrocini G, Costa C et al (2019) Merkel cell carcinoma: therapeutic update and emerging therapies. Dermatol Ther (Heidelb) 9(2):209–222
11.
Zurück zum Zitat Haanen JBAG, Carbonnel F, Robert C et al (2018) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv264–iv266PubMed Haanen JBAG, Carbonnel F, Robert C et al (2018) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv264–iv266PubMed
12.
Zurück zum Zitat Heinzerling L, Eigentler TK, Fluck M et al (2019) Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4(3):e491PubMedPubMedCentral Heinzerling L, Eigentler TK, Fluck M et al (2019) Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4(3):e491PubMedPubMedCentral
13.
Zurück zum Zitat Kähler KC, Hassel JC, Heinzerling L et al (2016) Management of side effects of immune checkpoint blockade by anti-CTLA‑4 and anti-PD‑1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 14(7):662–681PubMed Kähler KC, Hassel JC, Heinzerling L et al (2016) Management of side effects of immune checkpoint blockade by anti-CTLA‑4 and anti-PD‑1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 14(7):662–681PubMed
14.
Zurück zum Zitat Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768PubMed Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714–1768PubMed
16.
Zurück zum Zitat Ascierto PA, McArthur GA, Dréno B et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17(9):1248–1260PubMed Ascierto PA, McArthur GA, Dréno B et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 17(9):1248–1260PubMed
17.
Zurück zum Zitat Dummer R, Ascierto PA, Gogas HJ et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19(5):603–615PubMed Dummer R, Ascierto PA, Gogas HJ et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19(5):603–615PubMed
18.
Zurück zum Zitat Shirley M (2018) Avelumab: a review in metastatic Merkel cell carcinoma. Target Oncol 13(3):409–416PubMed Shirley M (2018) Avelumab: a review in metastatic Merkel cell carcinoma. Target Oncol 13(3):409–416PubMed
19.
Zurück zum Zitat Rapoport BL, van Eeden R, Sibaud V et al (2017) Supportive care for patients undergoing immunotherapy. Support Care Cancer 25(10):3017–3030PubMed Rapoport BL, van Eeden R, Sibaud V et al (2017) Supportive care for patients undergoing immunotherapy. Support Care Cancer 25(10):3017–3030PubMed
20.
Zurück zum Zitat Lemech C, Arkenau HT (2012) Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 6:53–66PubMedPubMedCentral Lemech C, Arkenau HT (2012) Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 6:53–66PubMedPubMedCentral
22.
Zurück zum Zitat Davis MP (2016) Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Canc Netw 14(7):915–922PubMed Davis MP (2016) Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Canc Netw 14(7):915–922PubMed
23.
Zurück zum Zitat Wang DY, Johnson DB, Davis EJ (2018) Toxicities associated with PD-1/PD-L1 blockade. Cancer J 24(1):36–40PubMedPubMedCentral Wang DY, Johnson DB, Davis EJ (2018) Toxicities associated with PD-1/PD-L1 blockade. Cancer J 24(1):36–40PubMedPubMedCentral
24.
Zurück zum Zitat Bala-Hampton JE, Bazzell AF, Dains JE (2018) Clinical management of pneumonitis in patients receiving anti-PD-1/PD-L1 therapy. J Adv Pract Oncol 9(4):422–428PubMedPubMedCentral Bala-Hampton JE, Bazzell AF, Dains JE (2018) Clinical management of pneumonitis in patients receiving anti-PD-1/PD-L1 therapy. J Adv Pract Oncol 9(4):422–428PubMedPubMedCentral
25.
Zurück zum Zitat Hesketh PJ, Kris MG, Basch E et al (2015) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261 Hesketh PJ, Kris MG, Basch E et al (2015) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261
26.
Zurück zum Zitat Furyk JS, Meek RA, Egerton-Warburton D (2015) Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. Cochrane Database Syst Rev 9:CD10106 Furyk JS, Meek RA, Egerton-Warburton D (2015) Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. Cochrane Database Syst Rev 9:CD10106
27.
Zurück zum Zitat Aapro M, Carides A, Rapoport BL (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20(4):450–458PubMedPubMedCentral Aapro M, Carides A, Rapoport BL (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20(4):450–458PubMedPubMedCentral
28.
Zurück zum Zitat Ziemer M, Koukoulioti E, Beyer S et al (2017) Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol 66(3):657–659PubMed Ziemer M, Koukoulioti E, Beyer S et al (2017) Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol 66(3):657–659PubMed
30.
Zurück zum Zitat Montano-Loza AJ, Czaja AJ (2015) Cell mediators of autoimmune hepatitis and their therapeutic implications. Dig Dis Sci 60(6):1528–1542PubMed Montano-Loza AJ, Czaja AJ (2015) Cell mediators of autoimmune hepatitis and their therapeutic implications. Dig Dis Sci 60(6):1528–1542PubMed
31.
Zurück zum Zitat Czaja AJ (2016) Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver 10(2):177–203PubMedPubMedCentral Czaja AJ (2016) Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver 10(2):177–203PubMedPubMedCentral
32.
Zurück zum Zitat Cheng R, Cooper A, Kench J et al (2015) Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30(4):657–666PubMed Cheng R, Cooper A, Kench J et al (2015) Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30(4):657–666PubMed
33.
Zurück zum Zitat McGuire HM, Shklovskaya E, Edwards J et al (2018) Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother 67(4):563–573PubMed McGuire HM, Shklovskaya E, Edwards J et al (2018) Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother 67(4):563–573PubMed
34.
Zurück zum Zitat Gençler B, Gönül M (2016) Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature. Dermatol Res Pract 2016:5361569PubMedPubMedCentral Gençler B, Gönül M (2016) Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature. Dermatol Res Pract 2016:5361569PubMedPubMedCentral
35.
Zurück zum Zitat Daud A, Tsai K (2017) Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist 22(7):823–833PubMedPubMedCentral Daud A, Tsai K (2017) Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist 22(7):823–833PubMedPubMedCentral
36.
Zurück zum Zitat Livingstone E, Zimmer L, Vaubel J et al (2014) BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chin Clin Oncol 3(3):29PubMed Livingstone E, Zimmer L, Vaubel J et al (2014) BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chin Clin Oncol 3(3):29PubMed
38.
Zurück zum Zitat Heinzerling L, de Toni E, Schett G et al (2019) Checkpoint-Inhibitoren. Diagnostik und Therapie von Nebenwirkungen. Dtsch Arztebl Int 116(8):119–126PubMedPubMedCentral Heinzerling L, de Toni E, Schett G et al (2019) Checkpoint-Inhibitoren. Diagnostik und Therapie von Nebenwirkungen. Dtsch Arztebl Int 116(8):119–126PubMedPubMedCentral
39.
Zurück zum Zitat Ben-Betzalel G, Baruch EN, Boursi B et al (2018) Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Eur J Cancer 101:229–235PubMed Ben-Betzalel G, Baruch EN, Boursi B et al (2018) Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Eur J Cancer 101:229–235PubMed
40.
Zurück zum Zitat Hua C, Boussemart L, Mateus C (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45–51PubMed Hua C, Boussemart L, Mateus C (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45–51PubMed
42.
Zurück zum Zitat Svoboda M, Poprach A, Dobes S et al (2012) Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review. Cardiovasc Toxicol 12(3):191–207PubMed Svoboda M, Poprach A, Dobes S et al (2012) Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review. Cardiovasc Toxicol 12(3):191–207PubMed
43.
Zurück zum Zitat Haverkamp W, Haverkamp F, Breithardt G (2002) Medikamentenbedingte QT-Verlängerung und Torsade de pointes: Ein multidisziplinäres Problem. Dtsch Arztebl 99:28–29 Haverkamp W, Haverkamp F, Breithardt G (2002) Medikamentenbedingte QT-Verlängerung und Torsade de pointes: Ein multidisziplinäres Problem. Dtsch Arztebl 99:28–29
44.
Zurück zum Zitat Zhang L, Jones-O’Connor M, Awadalla M et al (2019) Cardiotoxicity of immune checkpoint inhibitors. Curr Treat Options Cardiovasc Med 21(7):32PubMed Zhang L, Jones-O’Connor M, Awadalla M et al (2019) Cardiotoxicity of immune checkpoint inhibitors. Curr Treat Options Cardiovasc Med 21(7):32PubMed
46.
Zurück zum Zitat Läubli H, Balmelli C, Bossard M et al (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3:11PubMedPubMedCentral Läubli H, Balmelli C, Bossard M et al (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3:11PubMedPubMedCentral
47.
Zurück zum Zitat Varricchi G, Marone G, Mercurio V et al (2018) Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem 25(11):1327–1339PubMed Varricchi G, Marone G, Mercurio V et al (2018) Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem 25(11):1327–1339PubMed
48.
Zurück zum Zitat Banks M, Crowell K, Proctor A et al (2017) Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovasc Toxicol 17(4):487–493PubMedPubMedCentral Banks M, Crowell K, Proctor A et al (2017) Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovasc Toxicol 17(4):487–493PubMedPubMedCentral
49.
Zurück zum Zitat Ruggeri RM, Campenni A, Giuffrida G et al (2019) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest 42:745–756PubMed Ruggeri RM, Campenni A, Giuffrida G et al (2019) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest 42:745–756PubMed
50.
Zurück zum Zitat Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19(1):82–92PubMed Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19(1):82–92PubMed
51.
Zurück zum Zitat Albarel F, Gaudy C, Castinetti F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA‑4 antibody in melanoma. Eur J Endocrinol 172:195–204PubMed Albarel F, Gaudy C, Castinetti F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA‑4 antibody in melanoma. Eur J Endocrinol 172:195–204PubMed
53.
Zurück zum Zitat Quinkler M, Beuschlein F, Hahner S et al (2013) Nebennierenrinden-Insuffizienz – lebensbedrohliche Erkrankung mit vielfältigen Ursachen. Dtsch Arztebl Int 110(51–52):882–888PubMedPubMedCentral Quinkler M, Beuschlein F, Hahner S et al (2013) Nebennierenrinden-Insuffizienz – lebensbedrohliche Erkrankung mit vielfältigen Ursachen. Dtsch Arztebl Int 110(51–52):882–888PubMedPubMedCentral
55.
Zurück zum Zitat Grimm MO, Oppel-Heuchel H, Foller S (2018) Therapie mit PD-1/PD-L1- und CTLA-4-Immun-Checkpoint-Inhibitoren. Urologe A 57(5):543–551PubMed Grimm MO, Oppel-Heuchel H, Foller S (2018) Therapie mit PD-1/PD-L1- und CTLA-4-Immun-Checkpoint-Inhibitoren. Urologe A 57(5):543–551PubMed
56.
Zurück zum Zitat Balaji A, Verde F, Suresh K, Naidoo J (2017) Pneumonitis from anti-PD-1/PD-L1 therapy. Oncology (Williston Park) 31(10):739–746 (754) Balaji A, Verde F, Suresh K, Naidoo J (2017) Pneumonitis from anti-PD-1/PD-L1 therapy. Oncology (Williston Park) 31(10):739–746 (754)
57.
Zurück zum Zitat Johnson MJ, Hui D, Currow DC (2016) Opioids, exertion, and dyspnea: a review of the evidence. Am J Hosp Palliat Care 33(2):194–200PubMed Johnson MJ, Hui D, Currow DC (2016) Opioids, exertion, and dyspnea: a review of the evidence. Am J Hosp Palliat Care 33(2):194–200PubMed
58.
Zurück zum Zitat Moreira A, Loquai C, Pföhler C et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12–23PubMed Moreira A, Loquai C, Pföhler C et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12–23PubMed
59.
Zurück zum Zitat Johansen A, Christensen SJ, Scheie D et al (2019) Neuromuscular adverse events associated with anti-PD‑1 monoclonal antibodies: systematic review. Neurology 92(14):663–674PubMed Johansen A, Christensen SJ, Scheie D et al (2019) Neuromuscular adverse events associated with anti-PD‑1 monoclonal antibodies: systematic review. Neurology 92(14):663–674PubMed
60.
Zurück zum Zitat Glaus A, Crow R, Hammond S (1999) Fatigue in healthy and cancer patients II. A qualitative study on conceptual analysis. Pflege 12(1):11–19PubMed Glaus A, Crow R, Hammond S (1999) Fatigue in healthy and cancer patients II. A qualitative study on conceptual analysis. Pflege 12(1):11–19PubMed
61.
Zurück zum Zitat Vogelzang NJ, Breitbart W, Cella D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(3 Suppl 2):4–12PubMed Vogelzang NJ, Breitbart W, Cella D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(3 Suppl 2):4–12PubMed
62.
Zurück zum Zitat Yennurajalingam S, Frisbee-Hume S, Palmer JL et al (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31(25):3076–3082PubMed Yennurajalingam S, Frisbee-Hume S, Palmer JL et al (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31(25):3076–3082PubMed
63.
Zurück zum Zitat Bruera E, Driver L, Barnes EA et al (2003) Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 21:4439–4443PubMed Bruera E, Driver L, Barnes EA et al (2003) Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 21:4439–4443PubMed
64.
Zurück zum Zitat Minton O, Richardson A, Sharpe M et al (2008) A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 100(16):1155–1166PubMed Minton O, Richardson A, Sharpe M et al (2008) A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 100(16):1155–1166PubMed
65.
Zurück zum Zitat De Oliveira Campos MP, Riechelmann R, Martins LC et al (2011) Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med 17(6):505–512PubMed De Oliveira Campos MP, Riechelmann R, Martins LC et al (2011) Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J Altern Complement Med 17(6):505–512PubMed
66.
Zurück zum Zitat Yennurajalingam S, Reddy A, Tannir NM et al (2015) High-dose Asian ginseng (Panax ginseng) for cancer-related fatigue: a preliminary report. Integr Cancer Ther 14(5):419–427PubMed Yennurajalingam S, Reddy A, Tannir NM et al (2015) High-dose Asian ginseng (Panax ginseng) for cancer-related fatigue: a preliminary report. Integr Cancer Ther 14(5):419–427PubMed
67.
Zurück zum Zitat Cormie P, Zopf EM, Zhang X, Schmitz KH (2017) The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev 39(1):71–92PubMed Cormie P, Zopf EM, Zhang X, Schmitz KH (2017) The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev 39(1):71–92PubMed
68.
Zurück zum Zitat Dieli-Conwright CM, Orozco BZ (2015) Exercise after breast cancer treatment: current perspectives. Breast Cancer 21(7):353–362 Dieli-Conwright CM, Orozco BZ (2015) Exercise after breast cancer treatment: current perspectives. Breast Cancer 21(7):353–362
69.
Zurück zum Zitat Buchhold B, Arnold A, Lutze S et al (2017) Psychosocial distress and desire for support among patients with skin cancer. J Dtsch Dermatol Ges 15(8):791–799PubMed Buchhold B, Arnold A, Lutze S et al (2017) Psychosocial distress and desire for support among patients with skin cancer. J Dtsch Dermatol Ges 15(8):791–799PubMed
70.
Zurück zum Zitat Montazeri A (2009) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7:102PubMedPubMedCentral Montazeri A (2009) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7:102PubMedPubMedCentral
71.
Zurück zum Zitat Beutel ME, Blettner M, Fischbeck S et al (2009) Psychoonkologische Aspekte des malignen Melanoms. Hautarzt 60:727–734PubMed Beutel ME, Blettner M, Fischbeck S et al (2009) Psychoonkologische Aspekte des malignen Melanoms. Hautarzt 60:727–734PubMed
72.
Zurück zum Zitat Meiss F, Loquai C, Weis J et al (2018) Psychoonkologische Versorgung von Melanompatienten in zertifizierten Hautkrebszentren. J Dtsch Dermatol Ges 16(5):577–584PubMed Meiss F, Loquai C, Weis J et al (2018) Psychoonkologische Versorgung von Melanompatienten in zertifizierten Hautkrebszentren. J Dtsch Dermatol Ges 16(5):577–584PubMed
73.
Zurück zum Zitat Albrecht A, Meiss F, Zeiss T et al (2013) Psychoonkologische Versorgung für Melanompatienten: Konzeption und Implementierung. Hautarzt 64:927–930PubMed Albrecht A, Meiss F, Zeiss T et al (2013) Psychoonkologische Versorgung für Melanompatienten: Konzeption und Implementierung. Hautarzt 64:927–930PubMed
Metadaten
Titel
Supportivtherapie und Nebenwirkungsmanagement in der Dermatoonkologie
verfasst von
Dr. Laura von Dücker
Svea Hüning
Katharina Kähler
Patrick Terheyden
Dorothée Nashan
Publikationsdatum
12.11.2019
Verlag
Springer Medizin
Erschienen in
Die Dermatologie / Ausgabe 12/2019
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-019-04496-z

Weitere Artikel der Ausgabe 12/2019

Die Dermatologie 12/2019 Zur Ausgabe